INTRODUCTION
============

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited human renal disease (incidence 1 in 1000 live births) and is caused by mutations in two genes, *PKD1* (85%) and *PKD2* (15%) ([@B33]; [@B43]). ADPKD is an important cause of end-stage renal failure, accounting for ∼10% of patients on renal replacement therapy. The disease is characterized by the formation of fluid filled cysts in both kidneys of affected individuals, which ultimately result in end-stage renal failure. Other extrarenal manifestations of the disease include hypertension, cardiac valvular abnormalities, and cerebral aneurysms ([@B6]; [@B46]).

The ADPKD proteins polycystin (PC)-1 and PC2 have been shown to function as a heterodimeric complex ([@B17]; [@B30]), activating several key signaling pathways that in turn regulate diverse cellular functions, including proliferation, apoptosis, tubulogenesis, and fluid secretion. This is consistent with the largely overlapping renal and extrarenal phenotypes of PKD1 and PKD2 patients. PC1 and PC2 are likely to function together in many systems, but there is evidence to suggest they also can function independently ([@B33]).

PC2 is a 968-aa protein with six transmembrane spans, a pore-forming region, and cytoplasmic N- and C-terminal tails. Based on sequence homology, it has been adopted as a member of the transient receptor potential (TRP) channel superfamily (TRPP2), which is highly conserved throughout evolution and whose members function as nonselective cation channels responding to a wide range of stimuli. Although PC1 is believed to act at the plasma membrane (PM), PC2 has been shown to function at multiple locations, including primary cilia ([@B29]), basolateral membrane ([@B27]), and the endoplasmic reticulum (ER) ([@B21]). PC1 and PC2 have been shown to reconstitute a likely receptor--ion channel complex at the PM and PM---endoplasmic reticulum (ER) junctions, which regulates epithelial morphogenesis, whereas ER PC2 channels are likely to regulate determination of the left--right body axis ([@B13]).

Protein phosphorylation is a major posttranslational mechanism for regulating the function of most proteins, including members of the TRP family of ion channels ([@B47]). In most cases, phosphorylation leads to increased channel activity. For example, PKC phosphorylation on multiple sites increases the activity of TRPC1 ([@B1]) and TRPM4 ([@B16]; [@B31]). Similarly, phosphorylation may regulate PC2 channel activity ([@B4]; [@B22]).

In previous studies, work from our group and others had identified two mammalian PC2 serine residues that are phosphorylated ([@B4]; [@B42]). Phosphorylation at Ser^812^ is mediated by CK2 and is crucial for several functions, including its Ca^2+^ dependence; its retrograde trafficking via binding to the adaptor proteins, PACS-1 and PACS-2; and the cytoplasmic retention of the cell cycle regulatory protein Id2 ([@B4]; [@B20]; [@B25]). In addition, glycogen synthase kinase (GSK)-3--dependent phosphorylation at Ser^76^ has been shown to be critical for PC2 retention at the basolateral PM in vitro and essential for zebrafish pronephric development in vivo ([@B42]).

In a previous article, we reported that mutation of both Ser^76^ and Ser^812^ residues did not abolish PC2 phospholabeling ([@B42]). This led us to seek other potential phosphorylation sites and to define their functional significance. Using a combination of site-directed mutagenesis, in vitro kinase assays, and phospho-specific antibody mapping, we have identified a new phosphorylation site within the PC2 C terminus at Ser^801^ that contains an evolutionarily conserved recognition sequence for protein kinase D (PrKD), also known as human protein kinase C-μ (PKCμ). In nonciliated Madin-Darby canine kidney (MDCK) I cells with inducible PC2 expression, we demonstrate that phosphorylation at this site specifically regulates cell growth probably mediated through its permissive effects on Ca^2+^ transients from ER-located PC2 channels. Finally, a pathogenic mutation (Ser^804^) within the PrKD recognition consensus sequence abolished Ser^801^phosphorylation, indicating its likely physiological significance.

MATERIALS AND METHODS
=====================

Materials
---------

All chemicals were purchased from Sigma Chemical (Poole, Dorset, United Kingdom), unless otherwise stated. MDCK I and II cells were obtained from N. Simmons (University of Newcastle, Newcastle, United Kingdom) and the MDCK I FRT line was a kind gift of O. Frohlich (Emory University, Atlanta, GA). The human PKCμ plasmid was a gift of K. Pfizenmaier (University of Stuttgartm Stuttgart, Germany), and the pCMUIV-CD8 plasmid was a gift of S. Ponnambalam (University of Leeds, Leeds, United Kingdom). The PC2 antibodies p30 and 1A11 (gift of G. Wu, Vanderbilt University, Nashville, TN), which recognize the C-terminal 258 amino acids of human PC2, have been described previously ([@B34]; [@B24]). The phospho-serine rabbit polyclonal antibody was obtained from Invitrogen (Paisley, United Kingdom). The PKCμ antibody was obtained from Cell Signaling Technology (Danvers, MA), and the PC2 antibody G20 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Protein kinase inhibitors, ionomycin, hepatocyte growth factor (HGF) and epidermal growth factor (EGF) were from Calbiochem (Nottingham, United Kingdom).

Cell Culture and Transfection
-----------------------------

Human embryonic kidney (HEK)-293 and MDCK cells were cultured in DMEM supplemented with 10% fetal bovine serum. Transient transfection was carried out on cells cultured to 90% confluence by using Lipofectamine 2000 (Invitrogen) according to the manufacturer\'s instructions. MDCK I FRT cells ([@B11]) were transfected with the Tet repressor (pcDNA6/TR; Invitrogen) to generate a Flp-In T-Rex line, and several stable clones were selected in media containing blasticidin (5 μg/ml). Clones were screened for transient receptor (TR) activity by transient expression of a firefly luciferase reporter plasmid under the control of a cytomegalovirus/TetO2 promoter and subsequent induction with tetracycline (1 μg/ml). The clone with the highest inducible TR activity was then used to generate tetracycline inducible Flp-In hemagglutinin (HA)-PC2 or HA-PC2 mutant lines by cotransfecting pcDNA5/FRT/TO HA-PC2 and pOG44 Flp recombinase expression plasmids (Invitrogen) followed by selection in media containing hygromycin (100 μg/ml).

Immunoprecipitation and Immunoblotting
--------------------------------------

Total cell lysates were prepared and processed for immunoprecipitation and Western blotting as described previously ([@B30]). To assess the effect of serum stimulation on PC2 phosphorylation, stable or transiently transfected cells were seeded into 12-well plates and grown in complete medium to reach 90% confluence. Cells were then cultured in serum-free media for 24 h at 37°C to induce quiescence. Cells were stimulated with EGF (100 ng/ml) for 15 min or serum for 4 h. For inhibitor studies, cells were pretreated with inhibitors (Calbiochem) 4 h before stimulation. Cells were solubilized in detergent lysis buffer (50 mM Tris, 0.14 M NaCl, 1% Triton X-100, and 0.5% NP40) supplemented with Complete protease inhibitors and PhosStop phosphatase inhibitors (Roche Diagnostics, Mannheim, Germany).

λ-Phosphatase Assay
-------------------

After transfection, cells were cultured for 48 h and lysed in immunoprecipitation (IP) buffer containing Complete protease inhibitors for 1 h at 4°C on a rotator. Dephosphorylation was carried out by incubating 50 μg of total cell lysates with 200 U of λ-protein phosphatase (New England Biolabs, Hitchin, United Kingdom) for 30, 60, and 90 min at 30°C in reaction buffer (50 mM Tris-HCl, 0.1 mM EDTA, 5 mM dithiothreitol, and 0.01% Brij 35 pH 7.5) supplemented with 2 mM MnCl~2~. Reactions were terminated by addition of an equal volume of 2× sample loading buffer. Lysates were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting as described previously ([@B30]).

Generation of cDNA Constructs
-----------------------------

Site directed mutagenesis was carried out using the QuikChange site-directed mutagenesis kit (Stratagene, Stockport, United Kingdom) according to the manufacturer\'s instructions. The full-length *PKD2* plasmids PKD2Pk and TM4FL have been described previously and were used as templates ([@B28]; [@B34]). The PKD2 C-terminal construct (CT2) used in this study was synthesized by cloning the entire *PKD2* C terminus (680-968 aa) in frame with the extracellular and membrane-spanning region of pCMUIV-CD8 ([@B35]) to generate a CT2-CD8 fusion protein. PAGE-purified mutagenic primers were synthesized by Sigma Genosys (Cambridge, UK); primer sequences are available on request.

Immunofluorescence
------------------

Cells were grown on filters or coverslips and fixed with 4% paraformaldehyde for 10 min followed by permeabilization with phosphate-buffered saline (PBS)/0.1% Triton X-100. Blocking was carried out for 1 h with 5% milk powder/PBS, and primary antibodies were incubated overnight at 4°C in 3% bovine serum albumin/PBS. Controls included cells stained with primary antibody omitted, an irrelevant immunoglobulin (Ig)G1 monoclonal antibody (mAb) (Serotec, Kidlington, United Kingdom), or a nonimmune rabbit IgG fraction (Dako UK, Ely, Cambridgeshire, United Kingdom). Antibody binding was visualized using fluorescein isothiocyanate-conjugated goat ant-mouse IgG and Alexa Fluor 568-labeled goat anti-rabbit secondary antibodies. Slides were viewed using an Imaging Systems inverted IX71 microscope (Olympus, Tokyo, Japan) configured for multifluorescence image capture. Images were acquired and analyzed using SimplePCI imaging software (Compix, Hamamatsu, Sewickley, PA).

In Vitro Kinase Assay
---------------------

A pet32a+ plasmid encoding the PC2 C terminus (700--968 aa) in frame with 6xHis and thioredoxin sequences (Novagen, Nottingham, United Kingdom) was used to generate recombinant fusion protein ([@B34]). Constructs expressing HIS-tagged fusions were maintained in *Escherichia coli* strain BL21-DE3 and were induced with 1 mM isopropyl β-[d]{.smallcaps}-thiogalactopyranoside for 2 h. The fusion proteins were purified on HIS-Select nickel magnetic beads (Sigma Chemical) as described by the manufacturer, and purified recombinant proteins were visualized on SDS-PAGE gels stained with Coomassie Blue and Western blots stained with antibodies against thioredoxin (Invitrogen). In vitro phosphorylation was carried out on 2 μg of recombinant protein. Proteins were incubated for 10 min at 30°C in protein kinase C (PKC) buffer with \[^32^P\]γ-ATP, 3000 Ci/mmol (PerkinElmer Life and Analytical Sciences, Boston, MA) in the presence of rat brain-purified PKC (Millipore, Billerica, MA). Reactions were terminated by the addition of SDS-PAGE loading buffer and separated as described. After electrophoresis, gels were stained with Coomassie Blue, dried, and placed under x-ray film for autoradiography.

2-D Gel Electrophoresis
-----------------------

For two-dimensional electrophoresis, in vitro labeled protein samples were solubilized in IPG rehydration/sample buffer (8 M urea, 2% 3-\[(3-cholamidopropyl)dimethylammonio\]propanesulfonate, 50 mM dithiothreitol \[DTT\], 0.2% Bio-Lyte 3/10 ampholyte, and 0.001% bromphenol blue). The first dimension used ReadyStrip IPG Strips pH 3--10 (Bio-Rad Laboratories, Hemel, Hempstead, United Kingdom), and samples were focused for 50,000 V/h. The strips were removed from the focusing tray and equilibrated in 5 ml of buffer containing 50 mM Tris-HCl, pH 8.8, 6 M urea, 2% SDS, 30% glycerol, and 1% DTT. A second equilibration was carried out in 5-ml volume of the same buffer with 1.5% iodoacetamide substituted for the DTT. After equilibration, the ReadyStrip IPG strip was separated on a 11% SDS-PAGE gel. After second-dimension separation, samples were immunoblotted, and protein was detected using an anti-thio antibody (Invitrogen) as described above.

Small Interfering (siRNA) or Short Hairpin RNA (shRNA) Transfection
-------------------------------------------------------------------

Isoform-specific siRNA to human PrKD was chemically synthesized by Ambion (Austin, TX) according to the following sequence: 5′-GGAAGAGAUGUAGCUAUUAtt-3′. A scrambled negative control siRNA (Silencer) was purchased from Ambion. For knockdown of endogenous PC2 in MDCK cells, canine PKD2 targeting and control shRNAs cloned into pSuper vectors were used (gift of M. Kottgen, John Hopkins University, Baltimore, MD) ([@B45]). Transfection of siRNA and shRNA into cells was achieved using Lipofectamine reagent (Invitrogen). Analysis of knockdown was by immunoblotting for PrKD or PC2 48 h posttransfection.

Cell Proliferation Assay
------------------------

For the proliferation assay, 5000 cells from each cell line were seeded into 12 separate wells of a 96-well plate and cultured for 48 h. Cell proliferation was determined using a colorimetric immunoassay based on the measurement of 5-bromo-2′-deoxyuridine (BrdU) incorporation during DNA synthesis (Roche Diagnostics). The BrdU enzyme-linked immunosorbent assay (ELISA) was performed according to the manufacturer\'s instructions. In brief, cells were pulsed with 20 μl/well 100 μM BrdU solution for 2 h. Afterward, the culture medium was removed, and the cells were denatured with FixDenat solution and then incubated for 60 min with 1:100 diluted mouse anti-BrdU mAbs conjugated to peroxidase. After removing antibody conjugate, the substrate solution was added for 10 min. The absorbance was measured within 5 min at 450 nm with a reference wavelength at 690 nm using an ELISA plate reader. The blank corresponded to 200 μl of culture medium with or without BrdU. Each experiment was repeated three times.

Flow Cytometry
--------------

MDCK cells were cultured in 12-well dishes overnight, serum starved for 24 h, and then serum stimulated (10% fetal calf serum) for 24 h. Cells were then fixed with cold 70% ethanol, and suspended in propidium iodide (50 μg/ml) containing RNase A (0.1 mg/ml). After incubation at 37°C for 30 min, fluorescence-activated cell sorting (FACS) analysis was performed. Cell cycle stage analysis was carried out to determine the percentage increase in the number of proliferating cells in S/G2 after serum stimulation by using a FlowJo software package (TreeStar, Ashland, OR).

Apoptosis Assays
----------------

Apoptosis was induced in MDCK cells by incubating cells for 6 h with 20 μM ceramide or 0.1 μM staurosporine. Dimethyl sulfoxide (DMSO) was used for control treatments. Caspase-3 cleavage was quantified by FACS after incubation with a specific antibody to cleaved caspase-3 (Cell Signaling Technology). Experiments were carried out in triplicate.

Calcium Imaging
---------------

Control and stably transfected MDCK I FRT cells were grown in 96-well plates to subconfluent density. Cells were incubated in cell-permeant NW Fluo-4 (Invitrogen) for 30 min at 37°C and 30 min at room temperature according to the manufacturer\'s instructions in calcium free media. Changes in fluorescence intensity were determined based on observations of 50 randomly selected cells in each experiment. Cells were selected randomly before each experiment and the borders of the entire cell were outlined manually to eliminate any selective contribution from nonuniform distribution of the dye within cells. Dye-loaded cells were excited at 488 nm and increases in intracellular calcium were measured at an emission wavelength of 522 nm. Images were acquired every 10 s. Calcium transients were initiated by the addition of 10 μM ATP. Transient durations were measured from the start of the calcium transients until fluorescence changes returned to the prestimulus background. To confirm that calcium stores in each cell line were equivalent, calcium release from internal stores was measured after ionomycin (1 μM) or after blocking calcium reuptake with thapsigargin (5 μM). Images were acquired using SimplePCI imaging software (Compix, Hamamatsu) and analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).

Statistical Analysis
--------------------

Data are presented as mean values ± SEM. Student\'s *t* test was used for statistical analysis with a p value of \<0.05 indicating statistical significance.

RESULTS
=======

A PC2 Doublet Band Is Due to Phosphorylation at Ser^801^
--------------------------------------------------------

Sequence analysis of human PC2 by prediction programs PhosphoBase, DISPHOS 1.3, and NetPhos suggested that it could contain in excess of 100 predicted phosphorylation sites (data not shown). It had been shown previously that PC2 can be constitutively phosphorylated at two residues: Ser^76^ and Ser^812^ ([@B4]; [@B42]). Phosphorylation analysis was performed by ^32^P labeling PC2 in transiently transfected HEK-293 cells. Nevertheless, we were unable to eliminate PC2 phosphorylation by mutation of both sites ([@B42]). These findings led us to hypothesize that PC2 could be phosphorylated on alternative residues.

In multiple experiments, we observed that native or exogenous PC2 was often detectable as a doublet band by immunoblotting and hypothesized that the upper band might represent a specific phosphorylated form of PC2 ([Figure 1](#F1){ref-type="fig"}A). Dephosphorylation with the enzyme, λ phosphatase (which removes all phosphate groups from serine, threonine, or tyrosine residues) resulted in loss of the upper band in a time-dependent manner, confirming that the reduction in mobility on SDS-PAGE was indeed the result of phosphorylation ([Figure 1](#F1){ref-type="fig"}A). Phosphorylation at Ser^76^ has been visualized previously as a doublet band in N-terminal PC2 constructs ([@B42]). We found that a C-terminal PC2 construct was similarly detectable as a doublet band that could be reduced to a single band after treatment with λ-phosphatase ([Figure 1](#F1){ref-type="fig"}B).

![PC2 is phosphorylated in situ at Ser^801^. (A) Cell lysates from native mouse kidney cells (M8) and HEK-293 cells transfected with epitope-tagged PC2 (pkTag) were treated with λ-phosphatase for 0 and 60 min and analyzed by Western blotting with PC2- and pkTag-specific antibodies. A clear doublet band is seen in both native and transfected cells (see arrows). The top band disappears after incubation with the enzyme, demonstrating that it is due to phosphorylation. (B) Cell lysates from HEK-293 cells transfected with a C-terminal PKD2 construct were treated with λ-phosphatase for 0 and 90 min and analyzed by Western blotting with PC2-specific antibodies. A clear doublet band is seen. The top band disappears after incubation with the enzyme, demonstrating that it is due to phosphorylation. (C) To confirm the site responsible for the doublet band, single site mutants of CT2 were immunoblotted with a PC2-specific antibody to detect the presence of a phosphorylated banding pattern. Loss of the top phosphorylated band was only seen in cells transfected with the CT2 Ser^801^ mutant construct and not the Ser^812^ mutant construct. (D) To confirm the site responsible for the doublet band, single site mutants of PC2 were immunoblotted with an antibody directed to the pkTag epitope tag to detect the presence of a phosphorylated banding pattern. Loss of the top phosphorylated band was only seen in cells transfected with the PC2 Ser^801G^ mutant construct. Conversely, a phosphomimic S^801D^ mutant reduces the electrophoretic mobility of PC2, demonstrating that phosphorylation of Ser^801^ is sufficient to change the mobility of PC2. (E) Diagram showing the main structural motifs of PC2 relative to the position of previously described phosphorylation sites at Ser^76^ and Ser^812^ and the position of the new site at Ser^801^ reported in this study. (F) Active purified PKC was able to phosphorylate recombinant PC2 C terminus (CT2) in an in vitro kinase assay. The histogram shows that in vitro phosphorylation of the C-terminal of PC2 (CT2) by PKC is reduced by 53% (n = 3) when Ser^801^ is mutated to Gly (n = 3). Top, autoradiography. Bottom, Coomassie staining showing equal loading of recombinant protein used in the assay. An asterisk indicates a statistically significant difference (p \< 0.0065, Student\'s *t* test). (G) Two-dimensional gel analysis of phosphorylation of CT2 and CT2 S^801G^. After an in vitro kinase assay with purified PKC, samples were electrofocused under a pH gradient of 3--10 followed by separation by molecular weight on an 11% SDS-PAGE gel. Proteins were then immunoblotted with an anti-thio antibody. Phosphorylation results in a change in the isoelectric point of CT2. Multiple spots indicate multiple phosphorylation events. Wild-type CT2 separates isoelectrically into three distinct spots. CT2 containing a mutation at Ser^801^ shows a different pattern of isoelectric separation and has lost the most acidic spot indicating a reduction in overall phosphorylation. (H) A phospho-serine specific antibody (Invitrogen) recognizes HA-PC2 immunoprecipitated from HEK cells. Cell lysates prepared from HA-tagged PC2-expressing HEK cells were immunoprecipitated with an HA antibody. Samples were immunoblotted with an antibody to HA (top) and a phospho-serine antibody (bottom) to detect the presence of a phosphorylated isoform. A clear band was seen with the phospho-serine antibody indicating that PC2 is phosphorylated on serine residues. No signal was seen in mock transfected cells. (I) Immunoblot showing that an anti-phospho-serine antibody (Invitrogen) recognizes the full-length phosphorylated form of PC2 but not serine phosphorylation of the N-terminal domain of PC2 (NT2). (J) To confirm the site responsible for C-terminal phosphorylation, HA-tagged single serine site mutants of PC2 were immunoprecipitated from HEK cell lysates followed by detection with a phospho-serine antibody. Loss of the serine phosphorylated band was only seen in cells transfected with the Ser^801^ mutant construct. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody.](zmk0221096640001){#F1}

To determine the specific residues responsible for the mobility shift on Western blots, we substituted alanine or glycine at various combinations of five of the highest scoring predicted phosphorylation sites within the C terminus, i.e., Thr^721^, Ser^801^, Ser^812^, Ser^831^, and Ser^943^. Mutation of Thr^721^, Ser^812^, Ser^831^, and Ser^943^ did not alter doublet band formation (data not shown), whereas mutation of Ser^801^ to Gly^801^ resulted in complete loss of the upper band in both C-terminal ([Figure 1](#F1){ref-type="fig"}C) and full-length PC2 constructs ([Figure 1](#F1){ref-type="fig"}D). Confirming that phosphorylation at Ser^801^ was responsible for the mobility shift, a phosphomimic S^801D^ mutation resulted in the complete shift of PC2 to the upper band ([Figure 1](#F1){ref-type="fig"}D). These data suggest that PC2 is constitutively phosphorylated in situ on at least three serine residues ([Figure 1](#F1){ref-type="fig"}E).

Recombinant PC2 C Terminus Can Be Phosphorylated by PKC In Vitro
----------------------------------------------------------------

Ser^801^ in human PC2 is highly conserved in PC2 orthologues from higher and lower vertebrates, forming part of a consensus PKC recognition sequence and indicating its likely functional significance. To determine whether the C terminus of PC2 could act as a substrate for PKC, an in vitro kinase assay was performed using a recombinant C-terminal PC2 fusion protein (700--968 aa) and rat brain purified PKC, which contains a mixture of PKC isoforms ([Figure 1](#F1){ref-type="fig"}F). Analysis of three separate experiments confirmed that it could be phosphorylated by purified PKC. Mutation of Ser^801^ decreased (although it did not abolish) phosphorylation by PKC (p \< 0.05), implying the existence of other PKC sites.

We confirmed these results by two-dimensional (2-D) gel electrophoresis ([Figure 1](#F1){ref-type="fig"}G). Two-dimensional gel electrophoresis has been successfully used to identify many other phosphorylated proteins. The proteins are first separated in the first dimension by their isoelectric point and then by molecular weight in the second dimension. The 80-Da phosphate does not resolve phosphoproteins from their unphosphorylated counterparts in the molecular weight dimension. However, the negative charge of the phosphate does change the isoelectric point. The result is a "phosphorylation train"---a series of spots on the gel that correspond to the molecular weight of the protein and that are separated in the isoelectric focusing dimension according to the number of associated phosphate groups. Thus, the train also can reflect the existence of multiple phosphorylation events ([@B9]; [@B48]). The predicted p*I* of nonphosphorylated CT2 is pH 5.31. Phosphorylation of CT2 by PKC resulted in the appearance of three distinct spots on 2-D gels. The more acidic, hence more highly phosphorylated, forms are to the left of the gel. Mutation of Ser^801^ resulted in loss of the most negatively charged spot (highlighted circle) that also can be seen to be at a slightly higher molecular weight, mirroring what we had seen on a one-dimensional (1-D) gel. The finding that mutation of Ser^801^ does not completely eliminate in vitro phospholabeling of CT2 indicates that additional PKC sites are present.

Phospho-specific Antibody Mapping Identifies PC2 Phosphorylation at Ser^801^
----------------------------------------------------------------------------

Although the PC2 doublet band was often detected, it was difficult to reproduce the SDS-PAGE and Western blotting conditions consistently to resolve the small mobility shift on 1-D gels. Taking a parallel approach, we screened FIVE commercial phospho-serine antibodies generated to general phospho-serine consensus sequences for their ability to recognize phosphorylated PC2 after immunoprecipitation. Of the antibodies tested, one (Invitrogen) recognized phosphorylated PC2 (∼110 kDa) from transfected HEK cells ([Figure 1](#F1){ref-type="fig"}H) and native mouse collecting duct cells (see [Figure 3](#F3){ref-type="fig"}A).

To identify the specific phosphorylated PC2 serine residue detected by this antibody, we first tested an N-terminal PC2 construct (1-223 aa) that can be phosphorylated at Ser^76^ by GSK3 ([@B42]). This phospho-serine antibody did not recognize the PC2 N-terminal domain ([Figure 1](#F1){ref-type="fig"}I), suggesting that it might recognize a C-terminal serine residue instead. Using full-length *PKD2* cDNAs with specific mutations at the highest predicted C-terminal phosphorylation sites, we found that a Ser^801^ mutation abolished antibody binding ([Figure 1](#F1){ref-type="fig"}J).

PC2 Is Phosphorylated at Ser^801^ In Situ by Protein Kinase D
-------------------------------------------------------------

To confirm our in vitro kinase findings suggesting that PC2 Ser^801^ could be phosphorylated by purified PKC, we examined Ser^801^ phosphorylation in MDCK cells stably expressing PC2 after pretreatment with a series of PKC inhibitors. Surprisingly, although known PKC inhibitors such as staurosporine and Gö6976 resulted in complete loss of Ser^801^ phosphorylation, treatment with another common PKC inhibitor, bisindolylmalemide I, had no effect. Similarly, peptide inhibitors to PKC~ζ~, PKA, and calmodulin-dependent protein kinase II (CAMKII; KN93) did not significantly reduce Ser^801^ phosphorylation ([Figure 2](#F2){ref-type="fig"}B).

![Protein kinase D phosphorylates PC2 at Ser^801^. (A) The consensus PrKD phosphorylation motif (bold residues) and the corresponding motif in human (Q13563), mouse (O35245), and zebrafish (Q2VF27) PC2 are shown with the critical amino acids underlined. (B) To identify the kinase responsible for Ser^801^ phosphorylation, MDCK cells stably expressing HA-tagged PC2 were treated with specific kinase inhibitors. These included 0.1 μM staurosporine (broad-spectrum kinase inhibitor), 10 μM bisindolylmalemide I (BisI; PKC inhibitor), 10 μM Gö6976 (PKC inhibitor), 20 μM PKC peptide inhibitor (PKC inhibitor), 20 μM PKA peptide inhibitor (PKA inhibitor), and 20 μM KN93 (CAMKII inhibitor). PC2 was immunoprecipitated with an antibody directed to the HA epitope tag, followed by detection with a phospho-serine antibody. Loss of Ser^801^ phosphorylation was only seen in cells incubated with staurosporine and Gö6976. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. (C) MDCK cells stably expressing HA-tagged PC2 were pretreated with DMSO, 10 μM Gö6976, or 10 μM Gö6983 followed by 4-h serum stimulation. PC2 was immunoprecipitated with an antibody directed to the HA epitope tag, followed by detection with a phospho-serine antibody. Loss of Ser^801^ phosphorylation was seen only in cells incubated with Gö6976, suggesting that Ser^801^ could be phosphorylated by PrKD. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. (D) Expression of PrKD increases PC2 phosphorylation at Ser^801^. Cell lysates prepared from HEK cells coexpressing PrKD with HA-tagged PC2 or PC2 Ser^801G^ were immunoprecipitated with an HA antibody. Samples were immunoblotted with an antibody to PC2 (bottom) and a phospho-serine antibody (top) to detect the presence of Ser^801^ phosphorylation. A significant increase in phosphorylation was seen when PC2 was coexpressed with PrKD compared with PC2 alone. No signal was seen when PC2 Ser^801G^ was coexpressed with PrKD. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. An asterisk indicates a statistically significant difference (p \< 0.0001, Student\'s *t* test). (E) HEK cells were treated with control siRNAs or with validated siRNA specific to PrKD as described in *Materials and Methods*. PrKD knockdown was detected after immunoblotting of cell lysates with a PrKD-specific antibody (Santa Cruz Biotechnology). No reduction was seen in a control protein (calnexin). PC2 was immunoprecipitated with an antibody directed to the HA epitope tag, followed by detection with a phospho-serine antibody. A significant reduction in Ser^801^ phosphorylation was only seen in cells treated with PrKD-specific siRNA. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. (F) Loss of the Ser^801^-phosphorylated band was seen both in cells transfected with the Ser^801^ mutant construct as well as a pathogenic mutant S804N. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody.](zmk0221096640002){#F2}

In view of these findings, we reanalyzed the PKC consensus sequence around Ser^801^. The consensus recognition sequence of PrKD or PKCμ shows extreme selectivity for Leu at position −5 as well as selectivity for Arg at −3, Met at −1, and Phe at +4 ([@B32]). This recognition sequence is perfectly preserved around Ser^801^ in PC2 orthologues from higher and lower vertebrates ([Figure 2](#F2){ref-type="fig"}A). The initial description of PrKD as an atypical isoform of PKC and the inclusion of PrKD/PKCμ in reviews concerning the PKC family, which belongs to the AGC group (named for PKA, PKG, and PKC), contributed to a perception that PrKD belongs to the PKC family. However, it was noted from the outset that the catalytic domain of PrKD has highest sequence homology with myosin light chain kinase and CAMKs. Indeed, the three isoforms of PrKD are now classified as a new protein kinase family within the CAMK group, separate from the AGC group ([@B44]).

Because there are no known specific PrKD inhibitors, we compared the differential ability of two staurosporine derivatives, Gö6976 and Gö6983, to inhibit Ser^801^ phosphorylation. Gö6976 selectively inhibits classical PKC isoforms as well as PrKD, whereas Gö6983 suppresses the activity of all three PKC subgroups (classical, novel, and atypical) but not PrKD ([@B15]; [@B19]). As shown in [Figure 2](#F2){ref-type="fig"}C, treatment with Gö6976 but not Gö6983 inhibited Ser^801^ phosphorylation, suggesting that Ser^801^ was phosphorylated by PrKD. Consistent with this notion, bisindolylmalemide I is known to be a potent inhibitor of several PKC isoforms but not of PrKD ([@B15]).

We further confirmed this result by investigating Ser^801^ phosphorylation under conditions of PrKD overexpression and knockdown. As shown in [Figure 2](#F2){ref-type="fig"}D, enhanced Ser^801^ phosphorylation was observed in wild-type PC2 when cotransfected with PrKD; this was not seen in the PC2 Ser^801^ mutant. Efficient siRNA knockdown of endogenous PrKD in HEK cells also led to the abolition of PC2 Ser^801^ phosphorylation ([Figure 2](#F2){ref-type="fig"}E). These results indicate that PrKD is the physiological kinase for PC2 Ser^801^.

Although there are no known pathogenic mutations of PC2 at Ser^801^, a pathogenic mutation in a PKD2 pedigree resulting in an amino acid substitution of Ser^804^ to Asn^804^ has been reported previously ([@B38]). This residue forms part of the consensus binding domain for PrKD. Using full-length *PKD2* cDNAs with specific mutations at either Ser^801^ or S^804^, we found that a Ser^804N^ mutation also abolished phosphorylation at Ser^801^ as detected by the phosphoserine antibody ([Figure 2](#F2){ref-type="fig"}F).

PC2 Is Phosphorylated at Ser^801^ in Response to Growth Factors
---------------------------------------------------------------

PrKD has been shown to be activated after growth factor stimulation in many different studies ([@B39]; [@B44]). We therefore tested whether Ser^801^ phosphorylation could be altered by serum or EGF stimulation. As shown in [Figure 3](#F3){ref-type="fig"}A, a significant increase in endogenous PC2 Ser^801^ phosphorylation was detected after serum stimulation in mouse collecting duct kidney epithelial cells (M8) ([@B30]; [Figure 3](#F3){ref-type="fig"}A). The stimulatory effect of serum and EGF was similarly observed in both transiently transfected HEK cells ([Figure 3](#F3){ref-type="fig"}B) and stably transfected MDCK cells ([Figure 3](#F3){ref-type="fig"}C). ATP has been demonstrated to stimulate calcium induced calcium release through PC2 channels in this study (see [Figure 5](#F5){ref-type="fig"}) as well as others ([@B13]; [@B41]). To determine whether ATP also was able to stimulate phosphorylation of PC2, transiently transfected HEK cells were stimulated with 10 μM ATP for different time intervals from 0 to 60 min ([Figure 3](#F3){ref-type="fig"}E). Immunoblotting with the anti-phospho-serine antibody revealed low levels of phosphorylation of Ser^801^ at 0 min, which increased by 1 min and reached a peak 15 min after treatment with ATP ([Figure 3](#F3){ref-type="fig"}F) before decreasing to baseline (data not shown).

![Stimulation of Ser^801^phosphorylation in kidney epithelial cells. (A) Phosphorylation of endogenous PC2 at Ser^801^ after 4-h serum stimulation of serum starved M8 cells. PC2 was immunoprecipitated with an antibody directed to the C-terminal (G20) followed by detection with the phospho-serine antibody. The same blots were reprobed with the PC2 mAb 1A11 and show equal loading. (B) Serum and EGF stimulates Ser^801^ phosphorylation. HEK cells transiently expressing HA-tagged PC2 were serum starved for 24 h followed by stimulation with serum for 4 h or 100 ng/ml EGF for 15 min. PC2 was immunoprecipitated with an antibody directed to the HA epitope tag, followed by detection with a phospho-serine antibody. Significant increases in Ser^801^ phosphorylation were seen in stimulated cells (n = 3). Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. (C) MDCK cells stably expressing HA-tagged PC2 were serum starved for 24 h followed by 4-h serum stimulation or 100 ng/ml EGF for 15 min. PC2 was immunoprecipitated with an antibody directed to the HA epitope tag, followed by detection with a phospho-serine antibody. (D) Significant increases in Ser^801^ phosphorylation were seen in stimulated cells (n = 3). Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. An asterisk indicates a statistically significant difference (p \< 0.02, Student\'s *t* test). (E) ATP stimulates Ser^801^ phosphorylation. HEK cells transiently expressing HA-tagged PC2 were serum starved for 24 h followed by stimulation with 10 μM ATP for 0, 1, 5, and 15 min. Equal loading was confirmed by stripping and reprobing the same blot with an HA antibody. (F) Significant increases in Ser^801^ phosphorylation were seen in stimulated cells (n = 3) after densitometry of Western blots.](zmk0221096640003){#F3}

Phosphorylation of Ser^801^ Does Not Alter PC2 Localization in MDCK I Cells
---------------------------------------------------------------------------

PC2 has been shown to function in several subcellular compartments, and its localization can be dynamically regulated by phosphorylation at two residues, Ser^812^ and Ser^76^ ([@B20]; [@B42]). Of interest, Ser^801^ lies within a putative sequence important for ER retention (E787-S820) ([@B5]).

To investigate the effect of Ser^801^ phosphorylation on PC2 localization in polarized epithelia, we generated MDCK I clones stably expressing epitope-tagged wild-type or Ser^801^ PC2 under a tetracycline-inducible promoter ([Figure 4](#F4){ref-type="fig"}A). These cells showed low to absent basal HA-PC2 expression that was significantly induced by tetracycline. Staining for a variety of junctional proteins revealed no alterations in desmosomal (desmoplakin), adherens junction (E-cadherin), or tight junction (zona occludens-1) protein localization in the MDCK I FRT parent line or in the TR expression clones (data not shown). Unexpectedly, we could not detect primary cilia in these cells using an antibody to acetylated α-tubulin ([Figure 4](#F4){ref-type="fig"}B). The lack of cilia expression clearly related to its parental origin (MDCK I) rather than further selection because MDCK II cells clearly expressed primary cilia whereas MDCK I cells do not ([Figure 4](#F4){ref-type="fig"}B). In these cells, wild-type HA-PC2 localized completely with the ER protein calnexin with no detectable basolateral surface staining ([Figure 4](#F4){ref-type="fig"}B). Mutagenesis of Ser^801^ to glycine or aspartate did not alter PC2 ER localization in these cells. In transiently transfected MDCK II cells, wild-type HA-PC2 localized to primary cilia ([Figure 4](#F4){ref-type="fig"}C). Mutagenesis of Ser^801^ to glycine or aspartate did not alter PC2 cilial localization in these cells.

![Effect of Ser^801^ phosphorylation on the subcellular localization of PC2, protein--protein interactions, and proliferation. (A) Top, immunofluorescence of stably transfected MDCK cells. Expression of HA-tagged PC2 (red) was induced by the addition of 1 μg/ml tetracycline for 24 h. All lines showed clear inducible expression of PC2. Bar, 25 μm). Bottom, Western blotting demonstrates that protein expression of PC2 and Ser^801^ phosphorylation mutants were equally induced in the presence of 1 μg/ml tetracycline for 24 h. Equal loading was confirmed using calnexin as a control. (B) Immunofluorescence was carried out on 4% paraformaldehyde-fixed MDCK cells. Top, staining for primary cilia with an antibody to acetylated tubulin in cells grown to 5 d postconfluence on filters. MDCK II expressed well-developed primary cilia but MDCK I and MDCK I FRT showed no detectable primary cilia. Bottom, subcellular localization of PC2 in MDCK cells was not altered after mutation of Ser^801^ to either glycine (phospho-deficient) or aspartic acid (phospho-mimic). PC2 (green) was predominantly localized to the ER where it colocalized with calnexin (red). (C) Immunofluorescence was carried out on 4% paraformaldehyde-fixed MDCK II cells transiently transfected with either wild-type PC2, S^801G^, or S^801D^ mutants. Staining for primary cilia with an antibody to acetylated tubulin in cells grown to 5 d postconfluence on filters showed that MDCK II expressed well-developed primary cilia. Cilial localization of PC2 in MDCK II cells was not altered after mutation of Ser^801^ to either glycine (phospho-deficient) or aspartic acid (phospho-mimic). (D) Immunoblot detection with an antibody to HA-PC2 showed that under nonreducing conditions, PC2 forms two higher molecular weight oligomers. Mutation of Ser^801^ had no effect on PC2 oligomerization. (E) HEK cells were cotransfected with PC1-FLAG and PC2-Ser^801G^-pkTag. The blots represent protein immunoprecipitated from 0.5 mg of transient transfected HEK-293 total cell lysate by epitope-tagged (FLAG, or Pk) antibodies. Immunoblot detection with 7e12 (for PC1) or pkTag (for PC2) shows that polycystin complex formation was not disrupted by the S^801G^ mutation. (F) The proliferation rate of mock transfected MDCK cells or cells expressing PC2 or a Ser^801^ phospho-deficient or phospho-mimic mutation was compared using a BrdU ELISA assay (Roche Diagnostics). There was a significant decrease in proliferation in cells expressing PC2 (n = 9). An asterisk indicates a statistically significant difference (p \< 0.02). (G) The percentage increase in cells entering S/G2 phase of the cell cycle was significantly reduced after 24-h serum stimulation in cells expressing both PC2 and a Ser^801^ phospho-mimic mutation (n = 9). An asterisk indicates a statistically significant difference (p \< 0.05). (H) The percentage increase in cells entering S/G2 phase of the cell cycle was significantly increased after knockdown of PKD2 in MDCK cells compared with control cells (n = 6). An asterisk indicates a statistically significant difference (p \< 0.05).](zmk0221096640004){#F4}

Phosphorylation of Ser^801^ Does Not Alter Homomeric and Heteromeric PC2 Interactions
-------------------------------------------------------------------------------------

PC2 has been shown to interact with itself and with PC1 ([@B30]). Homophilic PC2 interactions have been shown to be important for its function as a homomeric channel as well as a heteromeric channel with PC1 ([@B10]; [@B13]). Mutagenesis of Ser^801^ did not alter the formation of PC2 oligomers ([Figure 4](#F4){ref-type="fig"}D) nor its ability to interact with PC1 by immunoprecipitation ([Figure 4](#F4){ref-type="fig"}E).

Effect of PC2 on Cell Proliferation Is Dependent on Ser^801^ Phosphorylation
----------------------------------------------------------------------------

PC2 has been shown previously to regulate cell proliferation by several pathways, including Id2, ERK and eIF2α ([@B25]; [@B14]; [@B26]). In agreement with previous studies, we observed that MDCK I cells expressing PC2 or a phosphomimic Ser^801^ mutant proliferated more slowly than control cells using a BrDU incorporation assay ([Figure 4](#F4){ref-type="fig"}F). This effect was lost in cells expressing the S^801G^ mutant protein. These findings were complimented by FACS cell cycle analysis. We observed a significant decrease in cells entering the S/G2 phase of the cell cycle after serum stimulation in MDCK I cells expressing PC2 or a phosphomimic Ser^801^ mutant ([Figure 4](#F4){ref-type="fig"}G). In contrast, MDCK I cells transfected with a PKD2 shRNA to knockdown endogenous PC2 showed a significant increase in the number of cells entering S/G2 compared with mock shRNA or control cells ([Figure 4](#F4){ref-type="fig"}H). Unlike the effect on proliferation, PC2 expression had no effect on basal apoptosis as measured by an FACS-based assay. Similarly, no difference in apoptosis induced by ceramide or staurosporine was observed among PC2, Ser^801^ mutant, and control cells (data not shown).

Polycystin-2 Phosphorylation at Ser^801^ Regulates ATP-induced Calcium Release
------------------------------------------------------------------------------

Phosphorylation of PC2 at Ser^812^ by CK2 has been reported to regulate the Ca^2+^ dependence of its channel activity ([@B4]). Previous studies have shown that the activation of purinergic receptors by ATP is able to stimulate ER Ca^2+^ release through PC2 channels in an inositol trisphosphate (IP~3~)-dependent manner ([@B12]; [@B13]). This has been confirmed in a recent study that reported a functional interaction between the IP~3~ receptor and PC2 in regulating Ca^2+^-induced Ca^2+^ release ([@B41]). We therefore used Ca^2+^ imaging assays to investigate whether Ser^801^ phosphorylation could alter channel activity in our MDCK I cell lines.

Induction of wild-type PC2 resulted in enhanced amplitude and duration of ATP-induced Ca^2+^ release from intracellular stores compared with uninduced or control cells ([Figure 5](#F5){ref-type="fig"}A). Mutation of Ser^801^ to glycine resulted in loss of this enhanced Ca^2+^ response, whereas the phosphomimic S^801D^ mutation had the same ATP response as wild-type PC2 ([Figure 5](#F5){ref-type="fig"}B).

![Ser^801^ phosphorylation regulates the function of ATP-stimulated PC2-mediated ER Ca^2+^-release channels. (A) Representative traces of Ca^2+^ transients elicited by ATP (10 μM) in control MDCK cells (MDCK FRT) and MDCK cells overexpressing PC2 with or without overnight incubation with 1 μg/ml tetracycline shown as the ratio of Ca^2+^-dependent Fluo-4 fluorescence over prestimulus background fluorescence (*F*/*F*~0~) (left). The area under the curve (AUC) (middle) of ATP-induced Ca^2+^ transients was measured in each cell line. Bars represent mean ± SEM for 50 cells. PC2-overexpressing cells differed significantly compared with mock or uninduced cells. The increases in Fluo-4 fluorescence (right) can be seen after ATP stimulation. MDCK cells were loaded with the Fluo-4 dye. All cells respond to ATP stimulus (10 μM, applied at 0 s) with an increase in intracellular calcium, visualized by an increase in bright pixels from the fluorescence of the indicator dye at 20 s (right). \*p \< 0.05. (B) Representative traces of Ca^2+^ transients elicited by ATP (10 μM) in control MDCK cells (MDCK FRT), and MDCK cells overexpressing either PC2, S^801G^, or S^801D^ shown as the ratio of Ca^2+^-dependent Fluo-4 fluorescence over prestimulus background fluorescence (*F*/*F*~0~) (left). The AUC (middle) of ATP-induced Ca^2+^ transients measured in each cell line. Bars represent mean ± SEM for 50 cells. PC2- and S^801D^-overexpressing cells differed significantly compared with control and S^801G^ cells (p \< 0.05). MDCK cells were loaded with the Fluo-4 dye. All cells respond to ATP stimulus (10 μM, applied at 0 s) with an increase in intracellular calcium, visualized by an increase in bright pixels from the fluorescence of the indicator dye at 20 s (right). \*p \< 0.05. (C) Representative traces of Ca^2+^ transients elicited by ATP (10 μM) in MDCK cells overexpressing PC2 after 2-h pretreatment with PKC inhibitors (10 μM Gö6976/Gö6983) shown as the ratio of Ca^2+^-dependent Fluo-4 fluorescence over prestimulus background fluorescence (*F*/*F*~0~) (left). The AUC (middle) of ATP-induced Ca^2+^ transients measured in each cell line. Bars represent mean ± SEM for 50 cells. Treatment of cells with Gö6976 significantly reduced the Ca^2+^ transients elicited by ATP compared with control (DMSO-treated) cells. PC2-expressing cells treated with G06983 showed a much smaller decrease in Ca^2+^-dependent Fluo-4 fluorescence. The increases in Fluo-4 fluorescence (right) can be seen after ATP stimulation. MDCK cells were loaded with the Fluo-4 dye. All cells respond to ATP stimulus (10 μM, applied at 0 s) with an increase in intracellular calcium, visualized by an increase in bright pixels from the fluorescence of the indicator dye at 20 s (right). \*p \< 0.05. (D) Representative traces of Ca^2+^ transients elicited by ionomycin (1 μm) in control MDCK cells (MDCK FRT), and MDCK cells overexpressing either PC2, S^801G^, or S^801D^ shown as the ratio of Ca^2+^-dependent Fluo-4 fluorescence over prestimulus background fluorescence (*F*/*F*~0~) (left). The AUC (middle) of ionomycin-induced Ca^2+^ transients measured in each cell line. Bars represent mean ± SEM for 50 cells. There was no significant difference between the cell lines. MDCK cells were loaded with the Fluo-4 dye. All cells responded to ionomycin stimulus (1 μM, applied at 0 s) with an increase in intracellular calcium, visualized by an increase in bright pixels from the fluorescence of the indicator dye at 20 s (right).](zmk0221096640005){#F5}

To determine whether inhibition of PrKD could alter ATP-mediated Ca^2+^ transients, we pretreated cells expressing wild-type PC2 with PKC inhibitors Gö6976 and Gö6983 ([Figure 5](#F5){ref-type="fig"}C). In agreement with our results showing that Gö6976 but not Gö6983 could block phosphorylation at Ser^801^ ([Figure 2](#F2){ref-type="fig"}C), pretreatment with Gö6976 resulted in a greater decrease in amplitude of the ATP induced Ca^2+^ release relative to Gö6983, compared with DMSO-treated controls. The smaller reduction observed with Gö6983 could indicate the importance of other unidentified PKC sites ([Figure 1](#F1){ref-type="fig"}, D and E). These data are consistent with the hypothesis that phosphorylation at Ser^801^ is essential for the normal function of PC2 as an ER Ca^2+^ release channel.

Calcium release after 1 μM ionomycin treatment was not significantly different between the cell lines tested confirming the integrity and equivalence of intracellular stores ([Figure 4](#F4){ref-type="fig"}D). Similar results were obtained with thapsigargin (data not shown).

The role of PC2 as an intracellular calcium release channel in these cells was confirmed by knockdown of endogenous PC2 levels in MDCK I cells ([Figure 6](#F6){ref-type="fig"}A). After 48 h, expression of PC2 was reduced by 80% ([Figure 6](#F6){ref-type="fig"}B) and resulted in a significant reduction in the amplitude and duration of ATP induced Ca^2+^ release from intracellular stores compared with control shRNA-transfected cells ([Figure 6](#F6){ref-type="fig"}, C and D).

![PKD2 knockdown reduces ATP-stimulated PC2 mediated ER Ca^2+^-release. (A) MDCK I cells were treated with control or PKD2 shRNA as described in *Materials and Methods*. PKD2 knockdown was detected after immunoblotting of cell lysates with a PC2-specific antibody. Calnexin was used as a loading control. (B) Significant decreases in PC2 expression were seen in PKD2 shRN-transfected cells after densitometry of western blots (n = 3). (C) Representative traces of Ca^2+^ transients elicited by ATP (10 μM) in MDCK I cells transfected with PKD2 or control shRNA is shown as the ratio of Ca^2+^-dependent Fluo-4 fluorescence over prestimulus background fluorescence (*F*/*F*~0~). (D) The area under the curve (AUC) of ATP-induced Ca^2+^ transients was measured in cell lines transfected with PKD2 or control shRNA. Bars represent mean ± SEM for 50 cells. Cells expressing PKD2 shRNA differed significantly from control cells.](zmk0221096640006){#F6}

DISCUSSION
==========

In this study, we have identified Ser^801^ as a previously unrecognized PrKD phosphorylation site in PC2/TRPP2 that is critical for its function as an ER Ca^2+^ release channel and in mediating downstream effects on cell proliferation. Previous studies had identified functional phosphorylation sites on PC2 at Ser^76^ ([@B42]) and Ser^812^ ([@B4]). Ser^801^ represents the third functional residue to be identified in PC2.

Phosphorylation of Ser^801^ was shown experimentally to be mediated by PrKD or PKCμ. In silico analysis of the sequence inclusive of and surrounding Ser^801^ show that it perfectly conforms to a PrKD recognition consensus sequence ([@B32]). Its evolutionary conservation to teleosts further indicates its likely functional importance in kidney morphogenesis. We have also demonstrated that a pathogenic PKD2 mutation (S^804N^) within the PrKD recognition sequence abolishes Ser^801^ phosphorylation, indicating its likely physiological significance.

PrKD is a highly versatile protein kinase that is predominantly located in the cytoplasm but can be recruited to perform distinct functions in various cellular compartments (e.g., plasma membrane, nucleus, Golgi, mitochondria) ([@B40]). PrKD is recruited to the plasma membrane by locally generated diacylglycerol where it is activated by PKC-mediated phosphorylation (mainly novel isoforms). In other organelles, alternative activation pathways (such as nonreceptor tyrosine kinases, Gβγ subunit binding and caspase cleavage) have been described previously ([@B44]).

PrKD has low constitutive activity but is known to be activated after growth factor stimulation in many different cell types ([@B39]; [@B44]). Consistent with this, phosphorylation of Ser^801^ was significantly increased by serum and EGF stimulation in our study. In a previous article, EGF was reported to inhibit plasma membrane PC2 channel activity through a phosphatidylinositol bisphosphate-dependent mechanism independent of PC2 phosphorylation ([@B27]). The phosphorylation-dependent regulation of channel activity that we describe thus represents a distinct mechanism for EGF in regulating function of the PC2 ER channel. EGF itself did not directly stimulate ER Ca^2+^ release in our assays (data not shown). Nonetheless, the time course of these events is very different (seconds vs. minutes to hours), suggesting that EGF or serum stimulation is permissive for PC2 channel activity. Similarly, ATP stimulated Ser^801^ phosphorylation over a similar time course to EGF, but this effect is clearly different to its acute effect on Ca^2+^ release.

Activation of PrKD by PKC-dependent phosphorylation of activation loop serines within the kinase domain is its major mode of activation, although PKC-independent activation also has been described ([@B3]; [@B23]; [@B8]). The inability of the PKC inhibitor Gö6983 to block Ser^801^ phosphorylation in our study may indicate that PrKD is activated independently of PKC. Future work will seek to examine the regulation of this pathway in more detail.

Our results also provide an alternative explanation for the link between growth factor stimulation and PC2 activity in the regulation of cell proliferation in MDCK I cells. Pkd2 heterozygous kidneys display a significantly increased basal and stimulated tubular proliferative index ([@B7]; [@B36]), and PC2 overexpression has been shown to inhibit cell proliferation and morphogenesis in vitro ([@B25]; [@B14]; [@B26]). Our results are consistent with these observations but extend them by showing the dependence of these effects on Ser^801^ phosphorylation. The effect seemed to be specific because there was no alteration in basal or stimulated apoptosis. A recent article has suggested that PC2 mediates a passive ER channel leak and that PC2 dosage could regulate sensitivity to certain apoptotic stimuli ([@B45]). We were unable to reproduce these findings in MDCK I cells. An unexpected finding was that MDCK I cells do not express primary cilia. It remains to be determined whether Ser^801^ phosphorylation of PC2 similarly controls cell growth in ciliated cells. Certainly, it does not alter the cilia localization of exogenous PC2 in MDCK II cells.

Previous studies have shown that PC2 can function as an ER Ca^2+^ release channel but did not distinguish between cilia-dependent and independent Ca^2+^ release ([@B21]). By using MDCK I cells that lack cilia, we were able to study ER channel activity in isolation from cilia-dependent Ca^2+^ release. MDCK I cells are thought to be of cortical collecting duct cell origin based on their high electrical resistance ([@B2]; [@B37]). In addition, they also can spontaneously initiate tubulogenesis in 3-D culture, unlike MDCK II cells ([@B18]). However, this is the first report of a difference in primary cilia expression between MDCK I and II cells.

We confirmed previous studies showing that PC2 mediated Ca^2+^ release from the ER can be stimulated by ATP ([@B12]; [@B13]). Ser^801^ lies in the linker region between a predicted EF-hand domain and the recently reported coiled-coil domain essential for C-terminal homodimerization ([@B13]). Phosphorylation at Ser^801^ seems to be permissive for this activity without altering the subcellular localization nor homophilic and heterophilic (with PC1) interactions of wild-type PC2. This function seems to be distinct from that of Ser^812^ phosphorylation that regulates the Ca^2+^ sensitivity of PC2 Ca^2+^ channels, possibly through regulating PC2--IP~3~ receptor interactions ([@B21]; [@B41]). Perhaps Ser^801^ phosphorylation may alter the conformation of this region to bind other regulatory proteins necessary for PC2 function. Future work will seek to investigate this possibility.

This article was published online ahead of print in *MBoC in Press* (<http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10-04-0377>) on September 29, 2010.
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